WARSAW, Ind., March 06, 2018 -- WishBone Medical. Inc. entered into a U.S. distribution agreement with Implanet to distribute the JAZZ implant system to treat spinal pathologies requiring vertebral fusion surgery in the Orthopedic Market.
The first procedure with WishBone Medical surgeons was completed in early 2018. “We are looking forward to expanding our Orthopedic spine products and the JAZZ system is our first product in this market,” said Nick Deeter, Chairman of the Board and CEO at WishBone Medical.
Mr. Deeter added, “WishBone Medical provides innovative implants and instruments in sterile packed, single use disposable kits and the JAZZ implant system is available in these single use kits.”
Ludovic Lastennet, CEO of Implanet said, “This disruptive single use, sterile packed business model of WishBone Medical compliments the Implanet America JAZZ platform of single use, sterile packed products.”
To learn more about WishBone Medical, visit www.WishBoneMedical.com
About WishBone Medical, Inc.
WishBone Medical is a Global pediatric orthopedic company, committed to providing anatomically appropriate innovative implants and instruments in sterile packed, single use, disposable kits, to prevent infection, reduce overall costs for our customers and achieve the best outcomes for children around the world who are still growing.
For further information, visit www.WishBoneMedical.com or call Andrew Miclot, Vice-Chairman and President at 574-306-4006.
About IMPLANET
Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ® latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ® has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 48 staff and recorded 2017 sales of €7.8 million. For further information, please visit www.implanet.com.
Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.
IMPLANET is listed on Euronext™ Growth market in Paris. ALIMP
To learn more about IMPLANET, visit www.Implanet.com
Please contact WishBone Medical at 574-306-4006 or email [email protected] for more information. To learn more about WishBone Medical, visit www.WishBoneMedical.com.
Andrew J. Miclot
Vice Chairman & President
WishBone Medical, Inc.
2150 North Pointe Dr.
Warsaw, IN 46582
(574)306-4006 – Office
(574)527-0964 - Mobile
[email protected]


Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Washington Post Publisher Will Lewis Steps Down After Layoffs
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



